Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00965185 · ClinicalTrials.gov registry record · NA

Statin Therapy to Improve Atherosclerosis in HIV Patients

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT00965185: Completed NA study, sponsored by Massachusetts General Hospital.

NCT00965185 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00965185, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function. In addition to known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects of statins will lead to a shift from pro-inflammatory monocyte and T cell subsets to less atherogenic subpopulations.

Interventions

  • DRUG Placebo
  • DRUG atorvastatin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2009-09
Est. Completion 2014-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00965185

The ClinicalTrials.gov registry entry for NCT00965185 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00965185 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00965185 about?

NCT00965185 is a clinical study titled "Statin Therapy to Improve Atherosclerosis in HIV Patients". In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function. In addition to known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects of statins will lead ...

What is the current status of trial NCT00965185?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2009-09. Estimated completion is 2014-01.

What interventions are being tested in trial NCT00965185?

The interventions under investigation include: Placebo (DRUG), atorvastatin (DRUG).

Who is sponsoring clinical trial NCT00965185?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.